The B6-hVEGFA mice were generated by replacing the mouse Vegfa gene sequence with the human VEGFA gene sequence, including the non-coding 3’ UTR region. This model expresses the human VEGFA protein. B6-hVEGFA mice can be used for mechanistic studies and efficacy evaluations of ophthalmic diseases such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and corneal neovascularization, as well as for tumor development and cancer drug research.

The B6-hPD-1/hVEGFA mouse is a humanized model obtained by crossbreeding hPD-1 mice (Catalog No. C001524) with B6-hVEGFA mice (Catalog No. C001555). This model can be used for research in drug development, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms related to human PD-1/VEGFA.

B6-hVEGFA/hANGPT2 mice are VEGFA and ANGPT2 double humanized mouse models obtained by mating VEGFA humanized mouse models (Catalog No. C001555) with ANGPT2 humanized mouse models (Catalog No. C001615). B6-hVEGFA/hANGPT2 mice express human VEGFA and ANGPT2 genomic sequences under the control of mouse promoters. This model is capable of reproducing human VEGFA and ANGPT2 and is a valuable tool for studying cancer, vascular diseases and autoimmune disorders. In addition, this model also provides a powerful preclinical research platform for evaluating the efficacy and mechanism of therapeutic drugs targeting VEGFA and ANGPT2.

The hVEGFA-TG mouse is a transgenic model generated by Cyagen. In this model, the expression of human VEGFA CDS is driven by the bovine rhodopsin promoter, allowing for specific overexpression of the human VEGFA gene in the retina without affecting the expression of the endogenous VEGFA gene. This model exhibits clear retinal and choroidal vascular lesions while maintaining complete eye structure and can naturally develop diseases. Anti-VEGF drugs such as Aflibercept have been evaluated for efficacy in this mouse model, demonstrating that Aflibercept can target and suppress VEGF expression, thereby alleviating retinal vascular lesions. As such, this model is well-suited for drug evaluation and mechanism research related to neovascular ophthalmic diseases.

Vegfa is located on chromosome 17 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Vegfa conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.

Ncoa1 is located on chromosome 12 of mice. Nuclease Technology was used to design sgRNA; Ncoa1 knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.

Fga is located on chromosome 3 of mice. Nuclease Technology was used to design sgRNA; Fga knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.

Ubb is located on chromosome 11 of mice. Nuclease Technology was used to design sgRNA; Ubb knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.

Aurkb is located on chromosome 11 of mice. Nuclease Technology was used to design sgRNA; Aurkb knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.

Ubb is located on chromosome 11 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Ubb conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.